Real-world use and outcomes of belimumab in childhood-onset lupus: A single-center retrospective study

贝里穆马布 医学 单中心 回顾性队列研究 内科学 系统性红斑狼疮 儿科 中心(范畴论) 疾病 B细胞激活因子 免疫学 抗体 结晶学 化学 B细胞
作者
Jordan E. Roberts,Cordelia Burn,Rebecca E. Sadun,Emily A. Smitherman,Scott E. Wenderfer,Mary Beth F. Son
出处
期刊:Lupus [SAGE Publishing]
卷期号:32 (9): 1111-1116 被引量:10
标识
DOI:10.1177/09612033231187752
摘要

Studies of real-world effectiveness of belimumab in adults with systemic lupus erythematosus have shown improved disease control and decreased oral glucocorticoid use. However, belimumab use outside of clinical trial settings has not been well studied in childhood-onset systemic lupus erythematosus (cSLE). We aimed to characterize indications for belimumab use and evaluate oral glucocorticoid doses and disease activity scores in the year following belimumab initiation at a single, large pediatric rheumatology center.We included children and young adults with cSLE who received ≥ 1 dose of belimumab. Repeated measures one-way ANOVA was used to compare SLEDAI-2K scores and prednisone-equivalent daily oral glucocorticoid doses at baseline, 6 months, and 12 months after belimumab initiation for those who continued therapy for a year.We identified 21 patients with cSLE who received ≥ 1 dose of belimumab. The median disease duration at belimumab initiation was 30.8 months [IQR 21.0-79.1]. At the time of belimumab initiation, 100% of patients were taking an antimalarial, 81% were on oral glucocorticoids, and 91% were on at least one conventional DMARD. Thirteen patients (62%) continued belimumab for ≥6 months and 11 (52%) for ≥12 months. Among those continuing belimumab for ≥12 months, median [IQR] oral prednisone daily doses in milligrams at baseline, 6 months, and 12 months were 12.5 [7.5-17.5], 9 [6.25-10], and 5 [5-9.5], p = 0.037, and median [IQR] SLEDAI-2K scores at baseline, 6 months, and 12 months were 8 [5.5-10.5], 6 [3.5-10], and 6 [6-8.5], p = 0.548, respectively.In our cohort of pediatric patients with lupus and moderate disease activity treated with belimumab for ≥12 months, daily oral glucocorticoid doses were significantly lower 6 and 12 months after belimumab initiation than baseline. Use in patients with active nephritis was uncommon. Further research is needed in a large, multicenter cohort to determine the real-world effectiveness of belimumab in children and develop guidelines for use.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
吴建文完成签到 ,获得积分10
1秒前
Popeye应助yue采纳,获得10
1秒前
唠叨的胡萝卜完成签到,获得积分10
2秒前
2秒前
3秒前
舒心冰彤完成签到 ,获得积分10
4秒前
4秒前
量子星尘发布了新的文献求助10
7秒前
oblivious完成签到,获得积分10
8秒前
mkb完成签到,获得积分10
8秒前
8秒前
向秋发布了新的文献求助10
9秒前
王云骢完成签到,获得积分20
10秒前
甜蜜鹭洋完成签到 ,获得积分10
10秒前
xuxuxuuxuxux完成签到,获得积分10
10秒前
11秒前
月光族完成签到,获得积分10
11秒前
树下发布了新的文献求助10
11秒前
滴滴完成签到,获得积分20
13秒前
14秒前
七安发布了新的文献求助30
14秒前
LeePsy完成签到,获得积分10
14秒前
15秒前
深情安青应助hbutsj采纳,获得10
15秒前
小璐璐呀完成签到,获得积分10
16秒前
明亮安双完成签到,获得积分20
17秒前
Lemon完成签到,获得积分10
17秒前
sci一区作者完成签到,获得积分20
18秒前
包容柜子发布了新的文献求助10
18秒前
hhllhh发布了新的文献求助10
19秒前
河丫应助阳洋洋采纳,获得10
19秒前
19秒前
落霞与孤鹜齐飞完成签到,获得积分10
20秒前
20秒前
20秒前
hbuhfl完成签到,获得积分10
21秒前
小瑜完成签到,获得积分10
22秒前
小蘑菇应助Lemon采纳,获得10
22秒前
betty2009完成签到,获得积分10
22秒前
星星完成签到,获得积分10
22秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
Research on Disturbance Rejection Control Algorithm for Aerial Operation Robots 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038426
求助须知:如何正确求助?哪些是违规求助? 3576119
关于积分的说明 11374556
捐赠科研通 3305834
什么是DOI,文献DOI怎么找? 1819339
邀请新用户注册赠送积分活动 892678
科研通“疑难数据库(出版商)”最低求助积分说明 815029